| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30008025 | HIV | ENSG00000101162.4 | protein_coding | TUBB1 | No | No | 81027 | Q9H4B7 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | TUBB1 |
|---|---|
| DrugBank ID | DB06772 |
| Drug Name | Cabazitaxel |
| Target ID | BE0000026 |
| UniProt ID | Q9H4B7 |
| Regulation Type | inhibitor |
| PubMed IDs | 23091336; 28567478; 32474655 |
| Citations | Nightingale G, Ryu J: Cabazitaxel (jevtana): a novel agent for metastatic castration-resistant prostate cancer. P T. 2012 Aug;37(8):440-8.@@Smiyun G, Azarenko O, Miller H, Rifkind A, LaPointe NE, Wilson L, Jordan MA: betaIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel. Cancer Chemother Pharmacol. 2017 Jul;80(1):151-164. doi: 10.1007/s00280-017-3345-2. Epub 2017 May 31.@@Zhu L, Zhang C, Lu X, Song C, Wang C, Zhang M, Xie Y, Schaefer HF 3rd: Binding modes of cabazitaxel with the different human beta-tubulin isotypes: DFT and MD studies. J Mol Model. 2020 May 30;26(6):162. doi: 10.1007/s00894-020-04400-w. |
| Groups | Approved |
| Direct Classification | Taxanes and derivatives |
| SMILES | [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4=CC=CC=C4)C(C)=C([C@@H](OC)C(=O)[C@]1(C)[C@H](C[C@H]1OC[C@@]21OC(C)=O)OC)C3(C)C |
| Pathways | |
| PharmGKB | PA165958401 |
| ChEMBL | CHEMBL1201748 |
